Werewolf Therapeutics outlines 2024 priorities: WTX-124/330 data, cash runway through Q1 2025

Werewolf Therapeutics, Inc.

WTX-124: updated monotherapy and initial combo data expected in 1H 2024; RDE selection and dose expansion planned.
WTX-330: preliminary Phase 1 monotherapy data expected in Q2 2024.
Preclinical candidates WTX-712 (IL-21) and WTX-518 (IL-18) advancing; preclinical data in 1H 2024.
Cash guidance extended: resources sufficient through at least Q1 2025.
Company seeking partners for non-oncology applications of INDUKINE platform, e.g., inflammatory diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.